FLGT — Fulgent Genetics, Inc. Stock Price, Chart & AI Report

Neutral Jan 30, 2026 • 09:57 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Esoteric Testing Research Report 2026 - Global $41.5+ Bn Market Trends, Opportunities, and Forecasts to 2031

The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.

DGX LH MYGN FLGT esoteric testing molecular diagnostics personalized medicine liquid biopsy

Sentiment note

Listed as a key player in the esoteric testing market but no specific performance metrics or developments mentioned in the article.

Positive Aug 1, 2025 • 20:26 UTC The Motley Fool • Eric Volkman

Why Fulgent Genetics Stock Was Crushing It on Friday

Fulgent Genetics reported Q2 earnings that exceeded analyst expectations, with revenue of $82 million, representing a 15% year-over-year increase, despite a 56% decrease in adjusted net income.

FLGT earnings genetic testing stock market Q2 results

Sentiment note

Company exceeded analyst expectations with higher-than-projected revenue, demonstrated diversification in laboratory services and clinical trials, and saw stock price rise over 8% despite broader market decline

Negative Jul 15, 2025 • 23:41 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating GoHealth, Semler, Adtran, and Fulgent and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating potential securities law violations by GoHealth, Semler Scientific, ADTRAN, and Fulgent Genetics, following DOJ investigations and financial reporting issues.

SMLR GOCO ADTN FLGT securities law DOJ investigation false claims financial reporting

Sentiment note

Received DOJ civil investigative demand regarding potential false claims under Uninsured Program

Negative Jul 1, 2025 • 01:00 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating GoHealth, Abacus, GoHealth, and Fulgent and Encourages Investors to Contact the Firm

Law firm investigating potential securities law violations for four companies, including DOJ investigations and stock price declines related to alleged false claims and kickback schemes.

GOCO SMLR ABL ABLLL securities law DOJ investigation false claims stock price decline

Sentiment note

Received DOJ civil investigative demand for potential false claims, resulting in 2.61% stock price decline

Negative Jun 23, 2025 • 16:53 UTC GlobeNewswire Inc. • N/A

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT

Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (FLGT) regarding potential false claims submitted under the Uninsured Program. The investigation follows Fulgent's disclosure in its annual report that it had received a civil investigative demand from the U.S. Department of Justice.

FLGT Fulgent Genetics false claims Uninsured Program Department of Justice

Sentiment note

The article indicates that Pomerantz LLP is investigating claims on behalf of Fulgent Genetics investors, suggesting potential wrongdoing or legal issues at the company.

Negative Jun 10, 2025 • 01:00 UTC GlobeNewswire Inc. • N/A

Bragar Eagel & Squire, P.C. Is Investigating Semler, ADTRAN, and Fulgent and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Semler Scientific Inc., ADTRAN Holdings, Inc., and Fulgent Genetics, Inc. regarding alleged violations of federal securities laws and/or other unlawful business practices.

SMLR ADTN FLGT Semler Scientific Inc. ADTRAN Holdings, Inc. Fulgent Genetics, Inc.

Sentiment note

The company disclosed that it had received a civil investigative demand from the U.S. Department of Justice regarding potential false claims submitted under the Uninsured Program, and its stock price fell following this news.

Negative Jun 3, 2025 • 01:00 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating EchoStar, Semler, ADTRAN, and Fulgent and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against EchoStar, Semler Scientific, ADTRAN Holdings, and Fulgent Genetics due to alleged violations of federal securities laws and other unlawful business practices.

SATS SMLR ADTN FLGT EchoStar Semler Scientific ADTRAN Holdings Fulgent Genetics

Sentiment note

Fulgent received a civil investigative demand from the DOJ regarding potential false claims submitted under the Uninsured Program, which led to a 2.61% drop in the company's stock price.

Neutral May 30, 2025 • 21:55 UTC GlobeNewswire Inc. • Edelson Lechtzin Llp

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Tempus AI Inc. (NASDAQ: TEM) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Tempus AI, Inc. (NASDAQ: TEM) due to allegations of providing potentially misleading business information to the investing public.

TEM SATS FLGT Tempus AI Inc. EchoStar Corporation Fulgent Genetics, Inc.

Sentiment note

The article mentions that Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Fulgent Genetics, Inc., but does not provide any further details about the nature of the investigation.

Neutral May 30, 2025 • 21:48 UTC GlobeNewswire Inc. • Edelson Lechtzin Llp

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of EchoStar Corporation (NASDAQ: SATS) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving EchoStar Corporation, resulting from allegations of providing potentially misleading business information to the investing public.

SATS TEM FLGT EchoStar Corporation Tempus AI Inc. Fulgent Genetics, Inc.

Sentiment note

The article only mentions that Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Fulgent Genetics, Inc., without providing any additional details. This suggests a neutral sentiment.

Negative May 25, 2025 • 01:19 UTC Benzinga • Business Wire

FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating potential securities law violations by Fulgent Genetics, Inc. related to the company's disclosure of a civil investigative demand from the DOJ regarding potentially false claims filed under the Uninsured Program.

FLGT Fulgent Genetics fraud investigation securities law violations

Sentiment note

The article indicates that the Schall Law Firm is investigating potential securities law violations by Fulgent Genetics, which suggests the company may have engaged in fraudulent or misleading practices.

Neutral Feb 28, 2025 • 15:44 UTC The Motley Fool • Jesterai

Fulgent Genetics Revenue Tops Estimates

Fulgent Genetics, a laboratory services and therapeutic development company, reported strong Q4 2024 results, exceeding analysts' expectations. The company saw robust revenue growth and a GAAP loss, highlighting the need to focus on revenue diversification and strategic execution.

FLGT Fulgent Genetics laboratory services therapeutic development revenue growth GAAP loss

Sentiment note

The article presents a mixed outlook for Fulgent Genetics. While the company exceeded expectations in Q4 2024, it also reported a GAAP loss, indicating the need to focus on revenue diversification and strategic execution. The neutral sentiment reflects the balanced nature of the company's performance and the challenges it faces.

Neutral Jul 3, 2024 • 12:03 UTC GlobeNewswire Inc. • N/A

Olink® Introduces Global Network of Certified Service Providers to Accelerate Protein Biomarker Discovery - GlobeNewswire

Olink, a global leader in proteomics, has introduced a network of Olink Certified Service Providers, which are leading contract research organizations and service labs around the world. This network aims to accelerate scientific discovery by making access to Olink's cutting-edge proteomics technology more accessible to researchers globally.

OLK FLGT WUXAY proteomics biomarker discovery service providers research acceleration

Sentiment note

Fulgent Genetics is mentioned as one of the members of the Olink Certified Service Provider network, but no additional information is provided about the company.